Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
AIPSS-MDS
CMML
MDS
artificial intelligence
leukaemia
prognosis
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
revised:
30
01
2024
received:
02
11
2023
accepted:
06
02
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
27
2
2024
Statut:
aheadofprint
Résumé
Chronic myelomonocytic leukaemia (CMML) is a rare haematological disorder characterized by monocytosis and dysplastic changes in myeloid cell lineages. Accurate risk stratification is essential for guiding treatment decisions and assessing prognosis. This study aimed to validate the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes (AIPSS-MDS) in CMML and to assess its performance compared with traditional scores using data from a Spanish registry (n = 1343) and a Taiwanese hospital (n = 75). In the Spanish cohort, the AIPSS-MDS accurately predicted overall survival (OS) and leukaemia-free survival (LFS), outperforming the Revised-IPSS score. Similarly, in the Taiwanese cohort, the AIPSS-MDS demonstrated accurate predictions for OS and LFS, showing superiority over the IPSS score and performing better than the CPSS and molecular CPSS scores in differentiating patient outcomes. The consistent performance of the AIPSS-MDS across both cohorts highlights its generalizability. Its adoption as a valuable tool for personalized treatment decision-making in CMML enables clinicians to identify high-risk patients who may benefit from different therapeutic interventions. Future studies should explore the integration of genetic information into the AIPSS-MDS to further refine risk stratification in CMML and improve patient outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Taiwan Ministry of Science and Technology
ID : 109-2314-B-002-221
Organisme : Taiwan Ministry of Science and Technology
ID : 109-2314-B-002-222
Organisme : Taiwan Ministry of Science and Technology
ID : 111-2314-B-002-280
Organisme : Taiwan Ministry of Health and Welfare
ID : 109-TDU-B-211-134009
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. https://doi.org/10.1182/blood-2016-03-643544
Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol. 2018;93(6):824-840. https://doi.org/10.1002/ajh.25056
Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005-3015. https://doi.org/10.1182/blood-2012-08-448548
Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6(2):e393. https://doi.org/10.1038/bcj.2016.5
Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121(12):2186-2198. https://doi.org/10.1182/blood-2012-08-449647
Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92(1):56-61. https://doi.org/10.1002/ajh.24573
Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124(18):2793-2803. https://doi.org/10.1182/blood-2014-06-583486
Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408-1417. https://doi.org/10.1182/blood-2016-02-699208
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. https://doi.org/10.1182/blood.V89.6.2079
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. https://doi.org/10.1182/blood-2012-03-420489
Moreno Berggren D, Kjellander M, Backlund E, Engvall M, Garelius H, Lorenz F, et al. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. Br J Haematol. 2021;192(3):474-483. https://doi.org/10.1111/bjh.16790
Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5(7):e333. https://doi.org/10.1038/bcj.2015.53
Aguirre LE, Gupta Jain A, Ball S, Al Ali N, Sallman DA, Kuykendall AT, et al. Refining risk stratification in CMML: a comprehensive assessment of the IPSS-M and other molecularly informed models. J Clin Oncol. 2023;41(16_Suppl):7020. https://doi.org/10.1200/JCO.2023.41.16_suppl.7020
Mosquera Orgueira A, Perez Encinas MM, Diaz Varela NA, Diaz Varela NA, Mora E, Díaz-Beyá M, et al. Machine learning improves risk stratification in myelodysplastic neoplasms: an analysis of the spanish group of myelodysplastic syndromes. HemaSphere. 2023;7(10):e961. https://doi.org/10.1097/HS9.0000000000000961
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:2200008.
Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
Ishwaran H, Kogalur U, Blackstone E, Lauer MS. Random survival forests. Ann Appl Stat. 2008;2(3):841-860.
Gerds T, Ohlendorff J, Ozenne B. riskRegression: risk regression models and prediction scores for survival analysis with competing risks. R package version 2023.03.22. 2023. [cited 2023 Mar 1]. Available from: https://CRAN.R-project.org/package=riskRegression
Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, et al. Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents. EBioMedicine. 2018;31:174-181. https://doi.org/10.1016/j.ebiom.2018.04.018
Calvo X, Roman-Bravo D, Garcia-Gisbert N, Rodriguez-Sevilla JJ, Garcia-Avila S, Florensa L, et al. Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. Blood Adv. 2022;6(13):3921-3931. https://doi.org/10.1182/bloodadvances.2022007359
Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, Bataller A, Charry P, Esteban D, et al. Real-world data on chronic myelomonocytic leukemia: clinical and molecular characteristics, treatment, emerging drugs, and patient outcomes. Cancers (Basel). 2022;14(17):4107. https://doi.org/10.3390/cancers14174107